Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates

Financial Performance - Metagenomi reported a quarterly loss of $0.54 per share, better than the Zacks Consensus Estimate of a loss of $0.68, but worse than a loss of $0.29 per share a year ago, representing an earnings surprise of +20.59% [1] - The company posted revenues of $8.51 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 20.50%, but down from $20.01 million in the same quarter last year [2] - Over the last four quarters, Metagenomi has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Metagenomi shares have declined approximately 49.3% since the beginning of the year, contrasting with the S&P 500's gain of 8.4% [3] - The current Zacks Rank for Metagenomi is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.67 on revenues of $7.07 million, and for the current fiscal year, it is -$2.48 on revenues of $32.4 million [7] - The outlook for the Medical - Drugs industry, where Metagenomi operates, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]